April 18, 2025
Damn that was boring
Looking at the results and listening to the call with the earnings announcement it just reinforces that when it comes to the CGM market this remains a duopoly between Abbott and Dexcom. It also reinforces the fact that the longer this remains a duopoly the harder it is for any CGM wannabe to gain any traction in the market.
Frankly there was nothing in the Abbott earnings release or call that came as a surprise. Growth was solid both internationally and domestically. If there was a silver lining in an otherwise very dull call was the mention that the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
